Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2017 08:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer

AUSTIN, Texas, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
September 06, 2017 07:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
August 31, 2017 16:05 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

AUSTIN, Texas, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
August 09, 2017 16:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results

AUSTIN, Texas, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
July 20, 2017 16:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Announces Leadership Change

AUSTIN, Texas, July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
July 10, 2017 16:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

AUSTIN, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
June 06, 2017 09:20 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Prices Public Offering of Common Stock

AUSTIN, Texas, June 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
June 05, 2017 16:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, June 05, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
May 23, 2017 08:00 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

--Announces three single agent expansion arms for AEB1102 solid tumor trials-- --Provides update on AEB1102 program in Arginase 1 Deficiency-- --Company names Aaron Schuchart as chief business...
May 16, 2017 16:01 ET | Source: Aeglea BioTherapeutics

Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference

AUSTIN, Texas, May 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right